endocrinology
Type 2 diabetes

Pneumonia protection may be another reason for people with T2D to take ACEi/ARB

In findings that have particular relevance in the COVID-19 pandemic, WA researchers have shown that ACE inhibitors and angiotensin receptor blockers (ARB) reduce the risk of pneumonia and influenza in people with type 2 diabetes. Use of ACE inhibitors or ARB was associated with a one third lower risk of hospitalisation for lower respiratory tract ...

Already a member?

Login to keep reading.


OR
© 2020 the limbic